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A
long with improving patients’ 
safety and reducing medical 
errors, one of the main 
challenges in medicine is implementing 
new strategies that have the potential 
to improve health outcomes. After the 
process of critically appraising clinical 
trials has ﬁ  nished, and the results 
of this appraisal are used to guide 
changes in clinical practice, it is then 
time to critically appraise the success of 
implementation.
In other words, are physicians 
really performing the new strategy 
in its entirety? If they are not, what 
are the barriers to implementation? 
Unfortunately, there is no “golden 
bullet” for successful implementation 
of new strategies in medicine [1,2]. 
However, common factors in the 
failure of implementation have been 
identiﬁ  ed, including environmental 
factors and factors related to the 
strategy itself [3]. 
Critically ill patients without diabetes 
often develop hyperglycemia. Until 
recently, it was common practice to 
treat only marked hyperglycemia in 
these patients, since hyperglycemia was 
considered to be an adaptive response 
to critical illness. But clinical trials have 
shown that so-called intensive insulin 
therapy (IIT) aiming at normoglycemia 
(i.e., blood glucose concentrations 
[BGC] between 80–110 mg/dl) can 
signiﬁ  cantly decrease mortality and 
morbidity of patients in the surgical 
and medical intensive care unit (ICU) 
[4–7]. 
We questioned whether IIT truly 
has become part of standard therapy 
in ICU patients and, if it is applied, 
to what extent? We performed a 
systematic search of the medical 
literature, in which we focused on 
surveys and reports on the practice 
of ITT (see Text S1). We searched 
for reasons why IIT had not been 
implemented. We compared factors 
that hindered implementation of IIT 
with factors hindering the adoption of 
other recently introduced strategies, 
both in ICU medicine and general 
medicine. 
Current Recommendations on IIT 
and Feared Complications
Following publication of the ﬁ  rst 
randomized controlled trial of IIT by 
van den Berghe and colleagues [4], 
several groups have recommended 
IIT as the standard of care for those 
who are critically ill. These groups 
include the Joint Commission 
on Accreditation of Healthcare 
Organization (http:⁄⁄www.jcaho.
org), the Institute for Healthcare 
Improvement (http:⁄⁄www.ihi.org), and 
the Volunteer Hospital Organization 
(http:⁄⁄www.vha.com). In addition, IIT 
is promoted as a part of a care bundle 
for sepsis by the American Thoracic 
Society (http:⁄⁄www.thoracic.org) and 
experts in the ﬁ  eld [8]. Also, IIT has 
become, to some extent, a benchmark 
for the quality of ICU care [9].
However, over the last few years, 
a number of commentators have 
expressed concern about the 
applicability of van den Berghe and 
colleagues’ ﬁ  ndings [4,5] to other 
settings [9–11]. These concerns include 
the relatively high mortality in relation 
to severity of illness among patients in 
the control group in one study [4]; the 
frequent administration of parenteral 
calories (which is unusual among most 
ICUs); the single-center design of the 
two studies [4,5]; and the fact that the 
investigators could hardly be blinded. 
The results of two much larger trials 
are awaited (the GLUControl trial 
[12] and the NICE-SUGAR trial [13]). 
In the mean time, different experts 
give different recommendations: 
some argue that although the 
evidence for IIT does not yet support 
a grade-A recommendation (based 
on the highest level of evidence), it 
does appear to be stronger than the 
evidence in support of a strategy of 
tolerating hyperglycemia [10]. Another 
suggestion is just to target a BGC of 
over 150 mg/dl [9], or to reserve IIT 
solely for critically ill patients after 
elective surgery [11].
One of the most frequently 
mentioned and feared complications 
of IIT is hypoglycemia. Indeed, 
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5.1% of patients treated with IIT in 
surgical intensive care versus 0.7% 
of control patients developed severe 
hypoglycemia (BGC is deﬁ  ned as 
less than 40 mg/dl) [4]. In medical 
ICU patients, severe hypoglycemia 
occurred even more often with IIT: 
18.7% of study patients versus 3.1% 
in the conventionally treated group 
encountered severe hypoglycemia 
[5]. Of note, the recent multicenter 
VISEP trial in Germany by the SepNet 
group was discontinued prematurely 
because of identical mortality rates in 
the treatment group and in the control 
groups but a higher incidence of 
hypoglycemia in the IIT group (12.1% 
versus 2.1%) [14]. Patients in the ICU 
who were sedated and patients with 
disturbances in the counter-regulatory 
responses to hypoglycemia are at risk 
for neuroglycopenia because of the 
absence of clinical symptoms of severe 
hypoglycemia. Neuroglycopenia may 
cause cerebral damage, epileptic 
insults, or even coma [15].
Current Practice of IIT
Surveys. McMullin and colleagues 
surveyed ICU nurses and ICU 
physicians on the blood-glucose-
concentration thresholds that they 
acted upon in ﬁ  ve university-afﬁ  liated 
multidisciplinary ICUs in Canada [16]. 
The reported clinically important 
threshold for hyperglycemia was 
remarkably high. Indeed, median 
threshold was 180 mg/dl (interquartile 
range [IQR] 162–216 mg/dl). The 
reported median clinically important 
threshold for hypoglycemia was 72 
mg/dl (IQR 54–72 mg/dl). ICU nurses 
acted on slightly but signiﬁ  cantly 
higher thresholds than ICU physicians 
(a difference of 9 mg/dl). 
Avoidance of hyperglycemia was 
judged most important for patients 
with diabetes, a recent seizure, 
advanced liver disease, or acute 
myocardial infarction. Surprisingly, 
avoiding hyperglycemia was judged 
unimportant for surgical patients—the 
targeted patients in van den Berghe 
and colleagues’ pivotal study on IIT in 
patients in the ICU [4]. In McMullin 
and colleagues’ paper [16], the 
authors gave no information regarding 
presumed risks of IIT, in particular the 
risk for hypoglycemia and the impact of 
this risk on the chosen BGC thresholds. 
Mackenzie and colleagues recently 
reported a survey on the use of IIT 
in large English hospitals [17]. Only 
25% of ICUs reported blood-glucose-
concentration targets to be similar 
to those used in the study by van 
den Bergh and colleagues [4]. Most 
ICUs in which IIT was performed 
reported higher normal blood-glucose-
concentration limits. Interestingly, 
most ICU nurses (82%) reported being 
afraid of hypoglycemia in the patients 
receiving IIT [18].
Mackenzie and colleagues’ ﬁ  ndings 
are partly in line with a recent survey 
in the Netherlands by three of us 
(MJS, PES, and HSM) [19]. Over 100 
participants of the annual meeting 
of the Dutch Society of Intensive 
Care were surveyed, most of them 
ICU physicians. Of the participants, 
69% stated that IIT was already 
being applied in their ICU, while 7% 
mentioned they would start with this 
intervention shortly. Of those that said 
they applied IIT in their ICU, 62% 
used some sort of intensive insulin 
protocol with sliding scales. Twenty-
six percent stated that their ICU used 
blood-glucose-concentration limits of 
80–110 mg/dl, 73% stated that their 
ICU used limits of 80–145 mg/dl, and 
2% stated that their ICU used limits 
of 80–180 mg/dl. Eighteen percent 
of respondents said that glycemic 
control was applied solely by ICU 
nurses, 16% said that it was applied by 
ICU physicians alone, and 65% said 
that it was applied by ICU nurses and 
ICU physicians as a team (1% did not 
answer the question). 
Recently, the Australian and New 
Zealand Intensive Care Society 
Clinical Trials Group (ANZICS-CTG) 
conducted a practice survey [20]. 
There were 45 afﬁ  liated ICUs that 
were E-mailed a blood-glucose survey, 
enquiring as to their familiarity with 
the van den Berghe and colleagues’ 
studies [4,5] and whether IIT had been 
adopted. If IIT had been adopted, 
respondents were asked to which 
groups of patients IIT was applied and 
the reasons for such selection. If IIT 
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Table 1. Studies Reporting Protocols and Practical Aspects of Intensive Insulin Therapy
Authors Reference Publication 
Year
Study Design Number of 
Patients
Persons 
Involved in IIT
Threshold of IIT 
(BGC, mg/dl)
Incidence 
of Severe 
Hypoglycemia
Conclusions 
by Author 
Regarding 
Safety
Krinsley et al. [6,41] 2004/2005 Before–after cohort 1,600 Less than 140 “Not changed” Safe
Kanji et al [21] 2004 Before–after cohort 100 Nurses 80–110  16%
Grey et al. [42] 2004 Randomized 
controlled trial
61 80–120 32%
Zimmerman et al. [43] 2004 Prospective cohort 342 Nurses 80–150  7%
Laver et al. [44] 2004 Prospective cohort
Goldberg et al. [45] 2004 Prospective cohort 118 Nurses 100–140  0.2% Safe
Goldberg et al. [46] 2004 Prospective cohort 52 Nurses 100–140  0.3% Safe
Ku et al. [47] 2005 Before–after cohort 156 Nurses Safe
Thomas et al. [48] 2005 Before–after cohort 891 Safe
Chant et al. [49] 2005 Before–after cohort 86 Nurses 90–140  0.2%–0.4% Safe
Bland et al. [50] 2005 Randomized 
controlled trial
10 Nurses “Rare” Safe
Moeniralam et al. [51] 2005 Before–after cohort 7,327 Nurses and 
physicians
80–140 3.3%–4.0% Safe
Taylor et al. [22] 2006 Before–after cohort 281 Physicians and 
nurses
120–150, 80–110 1.1%–3.4% Safe
See individual articles for details.
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had not been adopted, respondents 
were asked their reasons for failure to 
adopt this strategy. Sixty-four percent 
of ICUs responded to this survey; all 
were familiar with the studies on IIT, 
but only 10.3% had adopted IIT in all 
their patients. In 31% of responding 
centers, IIT was applied in selected 
patient groups, predominantly those 
that stayed in the ICU for over three 
days, those with sepsis, and postsurgical 
patients. The reasons for not applying 
IIT were due to concerns about the risk 
of hypoglycemia and concerns about 
the external validity of the two studies 
by van den Berghe and colleagues. 
Although these surveys may only be 
an incomplete reﬂ  ection of practice 
throughout the world, the striking 
similarities between their results at least 
suggest that IIT is far from being part of 
the standard care of critically ill patients.
Targets of intensive insulin therapy. 
Only two of the identiﬁ  ed studies 
[21,22] used BGC targets identical 
to those used in the two studies by 
van den Berghe et al. [4,5] (Table 
1). All other studies used different 
BGC thresholds, most of them with a 
higher upper limit (up to 150 mg/dl). 
Of interest, most studies found that 
higher BGC limits were deliberately 
chosen to facilitate acceptance of the 
protocol (i.e., because it was suspected 
that there would be an unacceptably 
high incidence of hypoglycemia when 
applying the limits used by van den 
Berghe and colleagues [4,5]). 
Incidence of hypoglycemia. The 
incidence of hypoglycemia varied 
from as low as 0.5% to as high as 
18.7%, when using the threshold 
of 40 mg/dl (Table 1). When using 
BGC less than 60 mg/dl and less 
than 72 mg/dl as a threshold for 
hypoglycemia, incidences were 32% 
and 29%, respectively. However, since 
the reliability of capillary blood-glucose 
measurements (blood obtained from a 
ﬁ  nger stick) are unsatisfactory (there 
is a high degree of imprecision and a 
high percentage of discordance [23]) 
in many of the reviewed studies, the 
incidence of hypoglycemia may have 
been higher or lower than reported. In 
most reports, IIT was considered a safe 
strategy.
Personnel involved in intensive 
insulin therapy. Although it was not 
always clearly stated in the papers, 
it seems that ICU nurses were the 
primary health-care workers involved 
in the application of the IIT protocol 
(Table 1). Only one study compared 
an ICU nurse-driven IIT protocol with 
a protocol applied by ICU physicians 
alone [22]. In this cohort study, three 
consecutive regimens were compared: 
IIT applied by ICU physicians with 
no speciﬁ  c targets, IIT applied by 
ICU nurses aiming at BGC between 
120–150 mg/dl, and IIT applied by 
ICU nurses aiming at the BGC used by 
van den Berghe and colleagues [4,5]. 
There was a signiﬁ  cant decrease in 
average daily BGC, from 190 to 163 
to 131 mg/dl in the three consecutive 
phases of the study. The incidence of 
severe hypoglycemia (deﬁ  ned as blood 
glucose concentration less than 40 
mg/dl) was similar between the groups, 
ranging between 1.1% and 3.4%. 
Remarkably, protocol compliance was 
reported to be low (only about 50% of 
orders were followed), and blood for 
BGC monitoring was at times obtained 
from a ﬁ  nger stick, which may be 
unreliable, as explained above.
Discussion
A systemic approach to the 
implementation of research evidence 
in daily practice is recommended. 
Indeed, before an intervention 
is implemented, different phases 
of accumulating evidence with 
respect to the intervention should 
be followed. A framework for the 
implementation of research evidence 
that leads to understanding of barriers 
and opportunities involved in the 
implementation of protocols or 
guidelines in health care has been 
proposed [2,24].
Identifying barriers for IIT is an 
important part of the process of 
its implementation [1]. Fears and 
barriers should be catalogued and 
rationalized. In fact, implementation 
of complex strategies requires a 
thorough social investigation before 
such strategies will be applied in daily 
practice. Considering IIT, we now 
recognize several hampering factors: 
concerns about the external validity 
of the two studies by van den Berghe 
and colleagues [4,5], the potential 
increased risk of hypoglycemia with 
associated neurological damage, and 
uncertainties on how (and who is) to 
apply and monitor IIT.
Factors hampering uptake of other 
ICU treatments. The hampering factors 
for the implementation of IIT in 
intensive care medicine are not unique, 
but are comparable to other strategies, 
both in intensive care medicine and in 
other medical specialties. This is nicely 
illustrated by the implementation 
processes of several strategies in the 
ICU in the last decade, such as the 
use of recombinant human-activated 
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Table 2. Hampering Factors for Implementation of Several New Strategies in Medicine
Strategy Target Groups Hampering Factors
External/Environmental Factors Factors Related to the Strategy Itself
Intensive insulin therapy Patients in the ICU Poor recognition of target groups, uncertainties on who is 
to apply the strategy in daily practice, concerns about the 
external validity of studies
Risk for (neuro)-hypoglycemia
rh-APC Patients in the ICU Poor recognition of target groups, costs of the strategy, 
concerns about the validity of the study
Risk for bleeding
Lung-protective mechanical 
ventilation using lower tidal 
volumes
Patients in the ICU Poor recognition of target groups, incorrect translation of 
calculation of ideal tidal volume for individual patients
Risk for hemodynamic side effects or increased 
need for sedation 
Vitamin-K antagonists Patients with atrial ﬁ  brillation Risk for bleeding
Lipid-lowering drugs Patients with an 
atherothrombotic event
Insufﬁ  cient knowledge regarding recent insights in the 
effectiveness of this treatment
See text for details on the several strategies.
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protein C (rh-APC) in severe sepsis 
[25], and the use of lung-protective 
mechanical ventilation in patients with 
acute lung injury [26] (Table 2). 
The use of rh-APC is hampered by 
two practical problems. First, the costs 
of APC treatment are high and are 
not well compensated at the hospital 
level, at least in several European 
countries [27]. Second, recognition 
of patients that may beneﬁ  t from APC 
can be difﬁ  cult, especially when a 
guideline has been developed aiming at 
restrictive use of APC. Another concern 
with the use of APC is the perceived 
increased risk of bleeding. It is difﬁ  cult 
to understand how this perception 
arose, given the overall beneﬁ  t of 
the treatment and the relatively low 
incidence of clinically signiﬁ  cant 
major bleeding, such as intracerebral 
bleeding. 
As regards the use of lower tidal 
volumes in patients with acute lung 
injury, one of the reasons why this 
strategy is not implemented in daily 
practice is simply that the calculation 
of tidal volumes is not adequately 
understood [28]. Also, patients with 
acute lung injury are often not easily 
recognized, causing many patients who 
may beneﬁ  t from lower tidal volumes 
not to be ventilated in a lung-protective 
way [29]. Finally, many of the suggested 
side effects of the use of lower tidal 
volumes, such as the potential increase 
in use of sedatives or hemodynamic 
instability, are now recognized to be no 
more than imaginary [30,31]. 
Factors hampering uptake of general 
medical treatments. In many other 
ﬁ  elds of medicine, implementation of 
evidence-based practice is difﬁ  cult, as 
shown by the insufﬁ  cient use of vitamin 
K–antagonist anticoagulant treatment 
in patients with atrial ﬁ  brillation 
[32,33] or the underuse of statins as 
secondary prophylaxis in patients with 
an atherothrombotic event [34,35]. In 
these cases, factors causing insufﬁ  cient 
implementation may include (among 
others) fear of complications (such as 
bleeding in the case of anticoagulant 
therapy), insufﬁ  cient knowledge 
regarding recent evidence on the 
effectiveness of these treatment 
options, or the additional workload 
for the physician, and the perceived 
burden for the patient caused by these 
interventions.
IIT and hypoglycemia. The 
observed incidence of hypoglycemia 
in the reviewed studies varies greatly, 
and depends on the deﬁ  nition of 
hypoglycemia, the target range for 
BGC, and the way in which BGCs were 
monitored. However, reporting the 
incidence of a BGC below a particular 
ﬁ  gure may be counterproductive 
[18,19]. Information on the proportion 
of time spent in the target range, above 
the target range, and below the target 
range would be more useful when 
evaluating published reports on the 
efﬁ  cacy and safety of IIT [36]. 
The most feared consequence of 
hypoglycemia is potentially irreversible 
neurological damage. How low does 
the hypoglycemia need to be, and 
for how long, for this complication 
to occur [18]? Repeated episodes of 
insulin-induced hypoglycemic coma 
for periods ranging from 45 minutes 
to three hours for treating opiate 
addiction and schizophrenia (in the 
1940s) were found to have minimal 
long-term effects and a mortality 
of less than 1% [37]. In addition, 
long-term follow-up of patients with 
diabetes mellitus randomized in a large 
prospective trial of IIT failed to detect 
any association between the frequency 
of severe hypoglycemia and cognitive 
decline [38]. Only subtle, reversible 
impairments of attention could be 
detected in patients without diabetes 
undergoing dynamic pituitary function 
assessment using hypoglycemic stress 
with BGC of 29 mg/dl [39]. 
In two years of IIT, Mackenzie et al. 
recorded 128 instances of hypoglycemia 
(blood glucose concentration less than 
40 mg/dl) out of 29,733 measurements, 
with a median value of 33 mg/dl (IQR 
25–36 mg/dl) and a median duration 
of 18.2 minutes (8.4–37.5 minutes) 
[18]. The incidence of hypoglycemia in 
their study decreased signiﬁ  cantly with 
time. The authors concluded that the 
risk of a patient suffering prolonged 
severe hypoglycemia was small and 
the risk of this resulting in signiﬁ  cant 
neurological damage was even smaller. 
In the two studies by van den Berghe 
et al., IIT in patients in the ICU was 
purely a nurse-driven protocol [4,5], 
but it is questionable whether nurses 
really want to adopt IIT, especially 
when the targets are set at the lower 
normal limits of BGC. In these studies, 
the nurses were dedicated research 
nurses, who may differ in their attitude 
toward IIT compared with routine ICU 
nurses. From personal experience, we 
know that nurses now and then might 
abandon the protocol, in particular 
at the lower normal limits, with the 
intention of preventing hypoglycemia. 
One survey suggested that IIT might 
be better if applied by ICU physicians 
[19]. However, in the one study that 
compared ICU physicians with ICU 
nurses [22], no differences in respect 
to safety (incidence of hypoglycemia) 
and efﬁ  cacy (average daily blood 
glucose concentration) were seen. 
In addition, ICU nurses’ continuous 
presence at the bedside may prevent 
deterioration of glucose control. 
Indeed, many of the predisposing 
factors for hypoglycemia in patients in 
the ICU are easily recognizable by ICU 
nurses, such as worsening nutritional 
status without adjustment for insulin 
infusion [40]. Future studies should 
focus on how to implement IIT in daily 
practice, putting special emphasis on 
which health professionals in the team 
should actually apply IIT guidelines, 
and to what extent.
Conclusion
At present, IIT is far from being 
standard practice. In addition, in those 
centers that report on their experiences 
with IIT, thresholds are set higher than 
in the two studies by van den Berghe 
and colleagues [4,5]. Several factors 
hamper the implementation of IIT, 
which are similar to factors that hinder 
the implementation of other evidence-
based strategies. Nevertheless, it is 
promising to see the large number of 
studies reporting on implementation of 
nurse-driven IIT in critically ill patients. 
In addition, several larger studies on 
the efﬁ  cacy of IIT are underway. When 
the process of critical appraisal of the 
published and upcoming trials on of IIT 
has ﬁ  nished, the time will have come 
to critically appraise implementation of 
IIT in daily practice.   
Supporting Information
Text S1. Search Strategy
Found at doi:10.1371/journal.
pmed.0030456.sd001 (21 KB DOC). 
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